Boston Scientific Corporation (BSX): Price and Financial Metrics
Boston Scientific Corporation (BSX)
Today's Latest Price: $33.60 USD
Updated Nov 27 5:00pm
Add BSX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BSX Stock Summary
- With a market capitalization of $48,112,561,022, Boston Scientific Corp has a greater market value than 95.57% of US stocks.
- Price to trailing twelve month operating cash flow for BSX is currently 31.51, higher than 86.57% of US stocks with positive operating cash flow.
- In terms of volatility of its share price, BSX is more volatile than merely 8.33% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Boston Scientific Corp are PHG, ETN, WM, ABB, and DD.
- Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.
BSX Stock Price Chart Interactive Chart >
BSX Price/Volume Stats
| Current price | $33.60 | 52-week high | $46.62 |
| Prev. close | $33.55 | 52-week low | $24.10 |
| Day low | $33.44 | Volume | 6,363,646 |
| Day high | $33.90 | Avg. volume | 10,735,873 |
| 50-day MA | $37.10 | Dividend yield | N/A |
| 200-day MA | $36.81 | Market Cap | 48.11B |
Boston Scientific Corporation (BSX) Company Bio
Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company was founded in 1979 and is based in Marlborough, Massachusetts.
BSX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $33.60 | $6.21 | -82% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Boston Scientific Corp. To summarize, we found that Boston Scientific Corp ranked in the 15th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Boston Scientific Corp ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is 0.12 -- which is good for besting just 21.92% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- Boston Scientific Corp's effective tax rate, as measured by taxes paid relative to net income, is at 101 -- greater than 97.23% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -82% |
| 1% | -82% |
| 2% | -82% |
| 3% | -81% |
| 4% | -81% |
| 5% | -81% |
Want more companies with a valuation profile/forecast similar to that of Boston Scientific Corp? See IDXX, TFX, FGEN, TECH, and ZBH.
Loading social stream, please wait...